Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1

Status

Completed 2Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 5OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 3Plasma cell 1

Conditions

Prostatic Neoplasms 3Multiple Myeloma 1

Interventions

Cyclophosphamide 2040Radiotherapy 1854Cisplatin 1820Carboplatin 1530Gemcitabine 1432Paclitaxel 1289Bevacizumab 1267Docetaxel 1200pembrolizumab 1196Oxaliplatin 1157Capecitabine 1140Fluorouracil 1059Dexamethasone 971Rituximab 918Nivolumab 908Magnetic Resonance Spectroscopy 858Etoposide 839Doxorubicin 823Drug Therapy 789Radiosurgery 774Irinotecan 774Cytarabine 736fludarabine 714Leucovorin 674Lenalidomide 608fludarabine phosphate 564Temozolomide 552Filgrastim 540Radiation 539Cetuximab 535

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × Interventional × tasquinimod × Clear all
NCT04405167 2025-10-07

Tasquinimod for the Treatment of Relapsed or Refractory Myeloma

University of Pennsylvania

Phase 1 Terminated
30 enrolled
Plasma cell

Multiple Myeloma

NCT02159950 2023-04-27

Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Roswell Park Cancer Institute

Phase 2 Completed
2 enrolled 7 charts
Genitourinary

Prostatic Neoplasms

NCT01513733 2018-09-04

CATCH

Duke University

Phase 1 Completed
25 enrolled
Genitourinary

Prostatic Neoplasms

NCT02396368 2015-11-20

Radium-223

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Withdrawn
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡